Reunion Neuroscience | Press Releases

Press Releases

U.S. FDA Grants Reunion Neuroscience’s Luvesilocin (RE104) Breakthrough Therapy Designation Status

MORRISTOWN, New Jersey, February 23, 2026 – Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to luvesilocin (formerly RE104) for the treatment of postpartum depression (PPD).

Reunion Neuroscience to Participate in Upcoming Investor Conferences

MORRISTOWN, New Jersey, February 19, 2026 – Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions, today announced its participation in the following upcoming conferences:

Reunion Neuroscience Presents Full Data from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD) at ACNP Annual Meeting

MORRISTOWN, New Jersey, January 20, 2026 – Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions, today announced the full results of RECONNECT, a Phase 2 clinical trial evaluating RE104 in adult female patients with moderate-to-severe PPD. The data were presented at the American College of Neuropsychopharmacology (ACNP) Annual Meeting and the poster presentation is now available on the Reunion website – please click here to access the poster presentation: RE104: A Novel Serotonergic Psychedelic 4-OH-DiPT Prodrug for the Treatment of Postpartum Depression.

Reunion Neuroscience Announces Program Updates and Highlights Anticipated 2026 Milestones

MORRISTOWN, New Jersey, January 12, 2026 – Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions, today announced program updates and anticipated 2026 milestones.

Reunion Neuroscience Announces First Patient Dosed in REKINDLE Phase 2 Clinical Trial of RE104 for the Treatment of Adjustment Disorder (AjD) in Cancer and Other Medical Illnesses

MORRISTOWN, New Jersey, September 30, 2025 – Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions, today announced the dosing of the first patient in REKINDLE, a Phase 2 clinical trial evaluating RE104 for the treatment of adjustment disorder (AjD) in patients with cancer and other medical illnesses. Topline results from the study are anticipated in 2027.

Reunion Neuroscience Announces Final Closing of its Series A Financing and Plans to Advance RE104 into Clinical Development for the Treatment of Generalized Anxiety Disorder (GAD)

MORRISTOWN, New Jersey, September 16, 2025 – Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions, today announced the closing of its Series A financing. Under the amended terms of the Series A financing, because certain efficacy parameters were met including achieving a statistically significant and clinically meaningful outcome for the RECONNECT study, the final tranche of the financing increased from $21 to $51 million bringing the total amount of the Series A financing to $133 million.

Reunion Neuroscience Announces Positive Topline Results from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)

MORRISTOWN, New Jersey, July 22, 2025 – Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions, today announced positive topline results from its RECONNECT Phase 2 clinical trial evaluating RE104 in adult female patients with moderate-to-severe postpartum depression (PPD).

Reunion Neuroscience Announces Publication of RE104 Phase 1 Data in The Journal of Clinical Psychopharmacology

MORRISTOWN, New Jersey, July 22, 2025 – Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions, today announced the publication of a manuscript entitled “Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous RE104: A Double-Blind, Randomized, Single Ascending Dose Placebo-Controlled Study,” describing the results of a Phase 1 study of RE104 in the peer-reviewed Journal of Clinical Psychopharmacology.

Reunion Neuroscience Announces Last Patient Dosed in RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)

MORRISTOWN, New Jersey, May 19, 2025 – Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions, today announced the completion of patient enrollment and the last patient dosed in RECONNECT, a Phase 2 clinical trial evaluating RE104 in adult female patients with moderate-to-severe postpartum depression (PPD). Topline results from the study, which enrolled 84 patients, are anticipated in the third quarter of 2025.

Reunion Neuroscience Presents REKINDLE, a Phase 2 Clinical Trial Evaluating RE104 for the Treatment of Adjustment Disorder (AjD) in Cancer and Other Medical Illnesses at the Anxiety & Depression Association of America (ADAA) 2025 Conference

MORRISTOWN, New Jersey, April 7, 2025 – Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions, presented the study design for the REKINDLE Phase 2 clinical trial, which will evaluate the safety and efficacy of RE104 for the treatment of adjustment disorder (AjD) in patients with cancer and other medical illnesses. The study design was presented in a poster session at the Anxiety & Depression Association of America (ADAA) 2025 Conference, held April 3-5, 2025, in Las Vegas, NV.

Reunion Neuroscience Announces Participation in Premiere Maternal Mental Health Event

MORRISTOWN, New Jersey, March 4, 2025 – Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions, today announced its participation in The Policy Center for Maternal Mental Health’s 2025 Maternal Mental Health (MMH) FORUM, taking place March 18-19, 2025.

Reunion Neuroscience Announces Program Updates and Highlights Anticipated 2025 Milestones

MORRISTOWN, New Jersey, January 6th, 2024 – Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions, today announced program updates and anticipated 2025 milestones. The Company also announced that Greg Mayes, President and Chief Executive Officer, will present a corporate overview and participate in a panel discussion entitled “Future of Psychedelics” at the 8th Annual Neuroscience Innovation Forum, taking place January 12, 2025 in San Francisco, CA.

Reunion Neuroscience Presented RE104 Phase 1 Data at the 2024 American College of Neuropsychopharmacology (ACNP) 63rd Annual Meeting

MORRISTOWN, New Jersey, December 11, 2024 – Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic therapeutic solutions, presented a poster detailing RE104 Phase 1 data at the American College of Neuropsychopharmacology (ACNP) 63rd Annual Meeting in Phoenix, Arizona.

Reunion Neuroscience Partners with Seleni Institute on Effective Diagnosis and Treatment of Maternal Mental Health Disorders

MORRISTOWN, New Jersey, October 9th, 2024 – Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic therapeutic solutions, today announced a new partnership with the Seleni Institute, a New York City based nonprofit that provides treatment and training regarding maternal mental health and wellness issues.

Reunion Neuroscience Appoints Mark Pollack, M.D., as Chief Medical Officer

MORRISTOWN, New Jersey, September 10th, 2024 – Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic therapeutic solutions, today announced the appointment of Mark Pollack, M.D., as Chief Medical Officer. Dr. Pollack previously served as a member of Reunion’s Advisory Board and is a highly accomplished psychiatrist with decades of leadership experience in neuroscience-focused drug development and clinical research. Pollack replaces Dr. Robert Alexander who will continue to remain involved with Reunion as a strategic advisor.

Reunion Neuroscience Joins the Is Mom OK? Initiative Recognizing Maternal Suicide Prevention Month

MORRISTOWN, New Jersey, September 4, 2024 – Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic therapeutic solutions, today announced its sponsorship of “Is Mom Ok?” in recognition of Maternal Suicide Prevention Month.

Reunion Neuroscience Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression

MORRISTOWN, New Jersey, July 23, 2024 – Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience, today announced that the first patient has been dosed in the RECONNECT Phase 2 clinical trial of RE104 for the treatment of postpartum depression (PPD). RE104 was designed to be a safe, fast-acting, single-dose therapy to benefit patients suffering from underserved mental health disorders, including PPD.

Reunion Neuroscience Announces Publication of Results from Early Preclinical Studies Demonstrating the Potential of RE104 for Development in Depressive Disorders

MORRISTOWN, New Jersey, May 20, 2024 – Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience, today announced the publication of the results of preclinical studies in ACS Chemical Neuroscience that validate the decisions to pursue RE104, a proprietary, patented prodrug of 4-OH-DiPT as a potential therapeutic in depressive disorders.

Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings

MORRISTOWN, New Jersey, May 2, 2024 – Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience, today announced the close of a $103 million Series A financing co-led by MPM BioImpact and Novo Holdings, with participation from Arkin Bio Capital, Mitsui & Co. Global Investment, Plaisance Capital, FemHealth Ventures, and Palo Santo.

Fluence and Reunion Neuroscience Inc. Announce Partnership on Phase 2 Clinical Study of RE104 for Postpartum Depression

New York, NY and Morristown, NJ, April 15, 2024 — Fluence, a global leader in education, training, and certification for practitioners of psychedelic medicine, and Reunion Neuroscience Inc., a venture backed clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience, today announced a strategic partnership to support the Phase 2 clinical study evaluating the safety and efficacy of RE104 in postpartum depression (PPD).

Reunion Neuroscience Inc. Announces Upcoming Presentations at the Anxiety and Depression Association of America (ADAA) 2024 Conference

Morristown, New Jersey, April 3, 2024 – Reunion Neuroscience Inc., a venture backed clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience, today announced that the clinical dataset from the Company’s Phase 1 study of its lead asset, RE104, will be presented in both a podium and poster at the Anxiety and Depression Association of America (ADAA) Conference taking place April 11-14, 2024, in Boston, MA.

Reunion Neuroscience Inc. to Participate in October Investor Conferences

WILMINGTON, October 5, 2023 – Reunion Neuroscience Inc., a venture backed clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today announced that Greg Mayes, Chief Executive Officer, will participate in the following investor conferences. Please contact your representative to schedule a 1×1 meeting with the company.

Reunion Neuroscience Inc. Announces FDA Clearance of IND Application to Initiate a Phase 2 Study of RE104 for the Treatment of Postpartum Depression

WILMINGTON, September 18, 2023 – Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 2 study of RE104, a novel serotonergic psychedelic compound, for the treatment of postpartum depression (PPD).

Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement

TORONTO, August 1, 2023 – Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) (“Reunion” or the “Company“), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions and MPM BioImpact (“MPM“) are pleased to announce the completion of the previously announced plan of arrangement (the “Arrangement“) effective today, whereby MPM acquired Reunion in an all-cash transaction valued at approximately US$13.1 million by way of a court-approved plan of arrangement under Section 192 of the Canada Business Corporations Act.

Reunion Neuroscience Inc. Obtains Final Court Order for Proposed Plan of Arrangement

TORONTO, July 14, 2023 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) (” Reunion ” or the ” Company “), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions is pleased to…

Reunion Neuroscience Inc. Shareholders Approve Proposed Plan of Arrangement

TORONTO, July 13, 2023 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) (” Reunion ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, is pleased to…

Reunion Neuroscience Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Common Shareholders to Receive Consideration of US$1.12 Per Share in Cash from the Arrangement Agreement with MPM BioImpact; Special Shareholder Meeting Scheduled July 12 Presented Encouraging Phase 1 Final Analysis at American Society of Clinical Psychopharmacology Annual Meeting TORONTO, June 29.

Reunion Neuroscience Announces US$13.1 Million Take-Private Transaction with MPM BioImpact

June 1, 2023 — Reunion Common Shareholders to Receive Consideration of US$1.12 Per Share in Cash Represents a 43.1% Premium to the 30-Day Volume Weighted Average Price Reunion Presents Encouraging Phase 1 Final Analysis at American Society of Clinical Psychopharmacology Annual Meeting, Enabling Advancement into …

Reunion Neuroscience Announces Presentation at 2023 Bloom Burton & Co. Healthcare Investor Conference

TORONTO , April 25, 2023 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today …

Reunion Neuroscience Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency

Reunion Neuroscience Appoints Dr. Fred Grossman to Board of Directors

Seasoned Psychiatrist and Global Pharmaceutical R&D Executive with Over Two Decades of Experience in Clinical Development, Including at Eli Lilly, Johnson & Johnson, Bristol Myers Squibb and Sunovion Pharmaceuticals TORONTO , April 03, 2023 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. …

Reunion Neuroscience Abstract Accepted for Poster Presentation at 2023 ASCP Annual Meeting

Full RE104 Dataset from Phase 1 Study and Overview of Phase 2 Trial to be Featured TORONTO , March 27, 2023 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing innovative and …

Reunion Neuroscience Files Lawsuit Against Mindset Pharma

TORONTO , March 13, 2023 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, has filed a …

Reunion Neuroscience to Participate in the Oppenheimer Annual Healthcare Conference

TORONTO , March 07, 2023 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today announced …

Reunion Neuroscience Provides Business Update and Reports Fiscal Third Quarter 2023 Financial Results

Feb. 14, 2023 — Company Completed Phase 1 Interim Data Analysis for Lead Asset, RE104, Which Showed Strong Safety and Tolerability with Differentiated Profile; Final Data Anticipated in Mid-2023 Continued to Strengthen Executive Team; Named Dr. Robert Alexander as Chief Medical Officer At December 31, 2022 …

Reunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday, February 14, 2023, at 8:30 A.M. ET

TORONTO , Feb. 02, 2023 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that the Company …

Reunion Neuroscience Appoints Robert Alexander as Chief Medical Officer

Company Adds Former Executive at Takeda, Pfizer, AstraZeneca, GSK and Merck to Leadership Team TORONTO , Jan. 18, 2023 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a biopharmaceutical company committed to developing innovative and patented …

Reunion Neuroscience Inc. Completes Interim Data Analysis for Phase 1 Clinical Trial with Novel Serotonergic Psychedelic RE104

First-in-Human Findings Highlight RE104’s Strong Safety and Differentiated Pharmacodynamic Profile, Setting Stage for Initiation of Phase 2 Development in Postpartum Depression TORONTO , Jan. 09, 2023 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the …

Reunion Neuroscience Inc. Provides 2023 Corporate Update

Jan. 4, 2023 — Company Plans to Report Phase 1 Interim Analysis for RE104 in Q1 2023 and Include Data Differentiating its Safety, Tolerability and Pharmacodynamic Profile from Other Psychedelics in Clinical Development On Track to Dose First Patient in Phase 2 Postpartum Depression Study in 2H 2023 President and …

Reunion Neuroscience Inc. to Participate in Upcoming Investor Conferences in December

TORONTO, Dec. 06, 2022 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today announced it will be participating in the following …

Reunion Neuroscience Puts in Place At-The-Market Equity Facility

TORONTO, Nov. 18, 2022 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) (“Reunion” or the “Company”), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today announced that it has …

Reunion Neuroscience Inc. Provides Business Update and Reports Fiscal Second Quarter 2023 Financial Results

Nov. 14, 2022 — Completed RE104 Phase 1 prespecified dose cohorts and on track to deliver interim Phase 1 analysis in the first calendar quarter of 2023. Appointed Greg Mayes as President and Chief Executive Officer, with Joseph del Moral moving into the role of Chairman…

Reunion Neuroscience Schedules Fiscal Second Quarter 2023 Conference Call for Monday, November 14, 2022, at 8:30 A.M. ET

TORONTO, Nov. 07, 2022 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or the “Company”), a biopharmaceutical company committed to developing innovative therapeutic solutions for underserved mental health conditions, announced today that it plans to release its …

Reunion Neuroscience to Present at Upcoming November Conferences

TORONTO, Oct. 31, 2022 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or the “Company”), a biopharmaceutical company committed to developing innovative therapeutic solutions for underserved mental health conditions, announced today that the Company will …

Reunion Neuroscience Appoints Chief Financial Officer and Vice President, Medical Affairs

Company Continues to Deepen Executive Bench with Life Science Industry Veterans TORONTO, Oct. 24, 2022 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or the “Company”), a biopharmaceutical company committed to developing innovative therapeutic solutions for …

Reunion Neuroscience CEO to Participate on Panel at 2022 Horizons Perspectives on Psychedelics Conference

“Raising Capital for Psychedelic Endeavors” Panel Part of Conference’s Psychedelic Business Forum TORONTO, Oct. 12, 2022 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) (“Reunion” or the “Company”), a leader in novel serotonergic psychedelic drug development committed to …

Reunion Neuroscience Inc. Announces Executive Changes

TORONTO, Oct. 07, 2022 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc . (TSX: REUN, NASDAQ: REUN) (” Reunion ” or the “ Company ”), a leader in novel psychedelic drug development committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor …

Reunion Neuroscience to Participate in the Cantor Neurology & Psychiatry Conference

TORONTO, Oct. 03, 2022 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (TSX: REUN, Nasdaq: REUN) (“Reunion”), or (“the Company”), a global leader in the discovery and development of innovative psychedelic-inspired therapeutics for improved mental health outcomes, today announced that management will …

Reunion Neuroscience Inc. Announces Results of Annual General and Special Shareholder Meeting

TORONTO, Sept. 29, 2022 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) (” Reunion ” or the “ Company ”) today announced the results of the votes held at its September 29, 2022 Annual General and Special Meeting of shareholders (the “ Meeting ”)…

Reunion Neuroscience Inc. Appoints Greg Mayes as President and Chief Executive Officer

Bringing a 20-Year Track Record of Success in the Biopharma Industry, Mayes Succeeds Joseph del Moral, Who Assumes the Role of Chairman TORONTO, Sept. 28, 2022 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) (“Reunion” or the “Company”), a leader in novel psychedelic drug …

Reunion Neuroscience Inc. to Participate in Upcoming Investor Conferences

TORONTO, Sept. 08, 2022 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (TSX: REUN, Nasdaq: REUN) (“Reunion”), or (“the Company”), a global leader in the discovery and development of innovative psychedelic-inspired therapeutics for improved mental health outcomes, today announced it will participate …

Reunion Neuroscience Inc. Announces 2022 Annual General Meeting of Shareholders

TORONTO, Aug. 31, 2022 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (TSX: REUN, Nasdaq: REUN) (“Reunion”), or (“the Company”), a global leader in the discovery and development of innovative of psychedelic-inspired therapeutics for improved mental health outcomes, today announced it has scheduled …

Field Trip Health & Wellness Ltd. Reports Fiscal First Quarter 2023 Financial and Operating Results

Aug. 29, 2022 — Completed corporate reorganization on August 11, 2022 separating the drug development (“Reunion Neuroscience Inc.” or “Reunion”) and healthcare and wellness (“Field Trip Health & Wellness” or “Field Trip”) divisions into two separate public companies (the “Spinout Transaction”)…

Reunion Neuroscience Inc. to Commence Trading on the Toronto Stock Exchange on August 17, 2022

TORONTO, Aug. 16, 2022 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (formerly, Field Trip Health Ltd., the ” Company ” or “ Reunion ”), a global leader in the discovery and development of innovative of psychedelic-inspired therapeutics for improved mental health outcomes, is pleased to announce …

Reunion Neuroscience Inc. (Formerly Field Trip Health Ltd.) Reports Fiscal First Quarter 2023 Financial Results, Completed Corporate Reorganization on August 11, 2022

Aug. 15, 2022 — Completed corporate reorganization, separating the Field Trip Discovery and Field Trip Health divisions into two separate companies. Field Trip Discovery renamed Reunion Neuroscience Inc. (“ Reunion ” or the “ Company ”), and will remain listed on the NASDAQ Stock Market and Toronto Stock Exchange …

Field Trip Announces Closing of Plan of Arrangement and $19.9 Million Private Placement Financing

Aug. 11, 2022 — Field Trip Health Ltd. has been renamed “Reunion Neuroscience Inc.” and remains listed on the NASDAQ Stock Market and Toronto Stock Exchange under the ticker symbol “FTRP” with such ticker symbol changing to “REUN” – Field Trip Health & Wellness Ltd. to be listed on the TSX Venture Exchange under …